Cite
MLA Citation
D. Kim et al.. “Brigatinib in crizotinib-refractory ALK+ non-small cell lung cancer (NSCLC): efficacy updates and exploratory analysis of target lesion response by baseline brain lesion status in the ALTA Trial.” Lung cancer, vol. 127, n.d., pp. S30–S31. http://access.bl.uk/ark:/81055/vdc_100077369501.0x000046